TEAM & GOVERNANCE

At Chiesi Ventures, we share a passion for rarity. Our people have all had some direct contact with rare diseases, personally and/or professionally.

 

Chiesi Ventures is managed by an Investment Committee reflecting the strategic collaboration between Chiesi and Pappas Capital and where Chiesi has majority. The members of the Investment Committee are reported below.

Giacomo Chiesi

Giacomo currently serves as Managing Partner at Chiesi Ventures and as Head of Global Corporate Development at Chiesi USA. He serves as a Board Member or Observer on the Boards of the Chiesi Group, Chiesi USA, Sentien Biotech, Glycomine, Aura Bioscience and Minoryx Therapeutics.

 

​In his tenure with the Chiesi Group he has directly structured and executed deals with $3B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital.

 

Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and IT companies in different countries. Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail business.

Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship and Finance.

Arthur M. Pappas

Art Pappas is CEO of Pappas Capital and Managing Partner of Pappas Ventures.

 

With more than 35 years guiding investment decisions in the life sciences industry, Art brings unique business insight and financial acumen to early stage venture capital investments and to company formation, entrepreneurial and corporate development opportunities